2,740
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

, , , , , ORCID Icon, , , & show all
Article: e1312044 | Received 15 Feb 2017, Accepted 23 Mar 2017, Published online: 08 May 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Miles Congreve, Giles A. Brown, Alexandra Borodovsky & Michelle L. Lamb. (2018) Targeting adenosine A2A receptor antagonism for treatment of cancer. Expert Opinion on Drug Discovery 13:11, pages 997-1003.
Read now

Articles from other publishers (19)

Hannah S. Sperber, Kyle A. Raymond, Mohamed S. Bouzidi, Tongcui Ma, Silvana Valdebenito, Eliseo A. Eugenin, Nadia R. Roan, Steven G. Deeks, Sandra Winning, Joachim Fandrey, Roland Schwarzer & Satish K. Pillai. (2023) The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency. Cell Reports 42:11, pages 113285.
Crossref
Niklas Bach, Riekje Winzer, Eva Tolosa, Walter Fiedler & Franziska Brauneck. (2023) The Clinical Significance of CD73 in Cancer. International Journal of Molecular Sciences 24:14, pages 11759.
Crossref
Yao Liu, Zhongliang Li, Xiaoguang Zhao, Jing Xiao, Jiacheng Bi, Xian-Yang Li, Guokai Chen & Ligong Lu. (2023) Review immune response of targeting CD39 in cancer. Biomarker Research 11:1.
Crossref
Andrea M. Chambers, Jiao Wang, Tram N. Dao, Kyle B. Lupo, Paige Veenhuis, Mitchell G. Ayers, Veronika Slivova, Aaron A. Cohen-Gadol & Sandro Matosevic. (2022) Functional expression of CD73 on human natural killer cells. Cancer Immunology, Immunotherapy 71:12, pages 3043-3056.
Crossref
Huihui Ding, Gongfu Wang, Zhen Yu, Huimin Sun & Lu Wang. (2022) Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway. Biomedicine & Pharmacotherapy 155, pages 113683.
Crossref
Odd L Gammelgaard, Mikkel G Terp, Christian Renn, Aran F Labrijn, Oliver Hamaker, Aaraby Y Nielsen, Henriette Vever, Soren WK Hansen, Morten F Gjerstorff, Christa E Müller, Paul WHI Parren & Henrik J Ditzel. (2022) Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity. Journal for ImmunoTherapy of Cancer 10:9, pages e004554.
Crossref
Mikkel G. Terp, Odd L. Gammelgaard, Henriette Vever, Morten F. Gjerstorff & Henrik J. Ditzel. (2021) Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology 15:12, pages 3299-3316.
Crossref
Macus Hao-Ran Bao & Carmen Chak-Lui Wong. (2021) Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells 10:7, pages 1715.
Crossref
Sifan Lyu, Yunshuo Zhao, Xiao Zeng, Xiaotong Chen, Qingqing Meng, Zhe Ding, Wenshan Zhao, Yuanming Qi, Yanfeng Gao & Jiangfeng Du. (2021) Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors. Journal of Chemical Information and Modeling 61:3, pages 1275-1286.
Crossref
James E. Stefano, Dana M. Lord, Yanfeng Zhou, Julie Jaworski, Joern Hopke, Tara Travaline, Ningning Zhang, Karen Wong, Amanda Lennon, Timothy He, Eva Bric-Furlong, Cornishia Cherrie, Tristan Magnay, Elisabeth Remy, William Brondyk, Huawei Qiu & Katarina Radošević. (2020) A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms. Journal of Biological Chemistry 295:52, pages 18379-18389.
Crossref
Alice Mogenet, Pascale Tomasini, Laurent Greillier & Fabrice Barlesi. (2020) Toxicités à prévoir avec les futures immunothérapies ou associations. Bulletin du Cancer 107:10, pages 1069-1078.
Crossref
Angela Ostuni, Monica Carmosino, Rocchina Miglionico, Vittorio Abruzzese, Fabio Martinelli, Daniela Russo, Ilaria Laurenzana, Agata Petillo & Faustino Bisaccia. (2020) Inhibition of ABCC6 Transporter Modifies Cytoskeleton and Reduces Motility of HepG2 Cells via Purinergic Pathway. Cells 9:6, pages 1410.
Crossref
Shi Yong Neo, Ying Yang, Julien Record, Ran Ma, Xinsong Chen, Ziqing Chen, Nicholas P. Tobin, Emily Blake, Christina Seitz, Ron Thomas, Arnika Kathleen Wagner, John Andersson, Jana de Boniface, Jonas Bergh, Shannon Murray, Evren Alici, Richard Childs, Martin Johansson, Lisa S. Westerberg, Felix Haglund, Johan Hartman & Andreas Lundqvist. (2020) CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation 130:3, pages 1185-1198.
Crossref
Simone de Leve, Florian Wirsdörfer & Verena Jendrossek. (2019) The CD73/Ado System—A New Player in RT Induced Adverse Late Effects. Cancers 11:10, pages 1578.
Crossref
Zheng Qiao, Xiaoping Li, Nannan Kang, Yue Yang, Chuyuan Chen, Tao Wu, Mingjun Zhao, Yu Liu & Xuemei Ji. (2019) A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy. International Journal of Molecular Sciences 20:5, pages 1057.
Crossref
Xin Chen, Xiaomin Song, Kang Li & Tong Zhang. (2019) FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
David Allard, Pavel Chrobak, Bertrand Allard, Nouredin Messaoudi & John Stagg. (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters 205, pages 31-39.
Crossref
Kavitha Gowrishankar, Lucy Birtwistle & Kenneth Micklethwaite. (2018) Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mammalian Genome 29:11-12, pages 739-756.
Crossref
Dipti Vijayan, Arabella Young, Michele W.L. Teng & Mark J. Smyth. (2017) Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer 17:12, pages 709-724.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.